- Home
- STEW vs JANX Comparison
STEW vs JANX Comparison
Compare STEW & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEW
- JANX
- Stock Information
- Founded
- STEW 1972
- JANX 2017
- Country
- STEW United States
- JANX United States
- Employees
- STEW N/A
- JANX N/A
- Industry
- STEW Investment Managers
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- STEW Finance
- JANX Health Care
- Exchange
- STEW Nasdaq
- JANX Nasdaq
- Market Cap
- STEW 1.6B
- JANX 1.4B
- IPO Year
- STEW N/A
- JANX 2021
- Fundamental
- Price
- STEW $17.86
- JANX $23.22
- Analyst Decision
- STEW
- JANX Strong Buy
- Analyst Count
- STEW 0
- JANX 7
- Target Price
- STEW N/A
- JANX $94.29
- AVG Volume (30 Days)
- STEW 84.5K
- JANX 665.3K
- Earning Date
- STEW 01-01-0001
- JANX 08-06-2025
- Dividend Yield
- STEW 3.71%
- JANX N/A
- EPS Growth
- STEW N/A
- JANX N/A
- EPS
- STEW 1.44
- JANX N/A
- Revenue
- STEW N/A
- JANX $9,336,000.00
- Revenue This Year
- STEW N/A
- JANX N/A
- Revenue Next Year
- STEW N/A
- JANX $1,470.82
- P/E Ratio
- STEW $10.34
- JANX N/A
- Revenue Growth
- STEW N/A
- JANX 28.12
- 52 Week Low
- STEW $11.97
- JANX $22.48
- 52 Week High
- STEW $14.94
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- STEW 63.21
- JANX 41.76
- Support Level
- STEW $17.45
- JANX $22.56
- Resistance Level
- STEW $17.40
- JANX $24.19
- Average True Range (ATR)
- STEW 0.17
- JANX 1.28
- MACD
- STEW 0.05
- JANX 0.02
- Stochastic Oscillator
- STEW 98.11
- JANX 15.32
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.